CN113151396A - 通过引物延伸进行载玻片上染色 - Google Patents
通过引物延伸进行载玻片上染色 Download PDFInfo
- Publication number
- CN113151396A CN113151396A CN202110180443.3A CN202110180443A CN113151396A CN 113151396 A CN113151396 A CN 113151396A CN 202110180443 A CN202110180443 A CN 202110180443A CN 113151396 A CN113151396 A CN 113151396A
- Authority
- CN
- China
- Prior art keywords
- strand
- oligonucleotide
- nucleotides
- dna
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010186 staining Methods 0.000 title description 58
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 283
- 238000000034 method Methods 0.000 claims abstract description 210
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 126
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 126
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 126
- 230000000295 complement effect Effects 0.000 claims abstract description 81
- 238000002372 labelling Methods 0.000 claims abstract description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 497
- 239000002773 nucleotide Substances 0.000 claims description 417
- 125000003729 nucleotide group Chemical group 0.000 claims description 417
- 239000000523 sample Substances 0.000 claims description 221
- 239000000203 mixture Substances 0.000 claims description 99
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 84
- 230000002441 reversible effect Effects 0.000 claims description 57
- 102000003960 Ligases Human genes 0.000 claims description 33
- 108090000364 Ligases Proteins 0.000 claims description 33
- 238000000799 fluorescence microscopy Methods 0.000 claims description 28
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 18
- 239000002751 oligonucleotide probe Substances 0.000 claims description 18
- 108091023037 Aptamer Proteins 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 description 223
- 230000015572 biosynthetic process Effects 0.000 description 174
- 238000003786 synthesis reaction Methods 0.000 description 174
- 210000004027 cell Anatomy 0.000 description 126
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- 239000000872 buffer Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 230000003321 amplification Effects 0.000 description 32
- 238000001514 detection method Methods 0.000 description 32
- 238000003199 nucleic acid amplification method Methods 0.000 description 32
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- 210000004989 spleen cell Anatomy 0.000 description 26
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 25
- 229960000523 zalcitabine Drugs 0.000 description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 238000012546 transfer Methods 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 230000000415 inactivating effect Effects 0.000 description 18
- 238000005096 rolling process Methods 0.000 description 18
- 238000003860 storage Methods 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- -1 muscle fibers Proteins 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 15
- 238000004132 cross linking Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 230000015654 memory Effects 0.000 description 14
- 230000000903 blocking effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 7
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 7
- 229940045145 uridine Drugs 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000004061 bleaching Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- MGJYOHMBGJPESL-UHFFFAOYSA-L disodium;1-[8-(2,5-dioxo-3-sulfonatopyrrolidin-1-yl)oxy-8-oxooctanoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].[Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S([O-])(=O)=O)CC1=O MGJYOHMBGJPESL-UHFFFAOYSA-L 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241001104043 Syringa Species 0.000 description 2
- 235000004338 Syringa vulgaris Nutrition 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- WLKAMFOFXYCYDK-UHFFFAOYSA-N [5-amino-4-[[3-[(2-amino-4-azaniumyl-5-methylphenyl)diazenyl]-4-methylphenyl]diazenyl]-2-methylphenyl]azanium;dichloride Chemical compound [Cl-].[Cl-].CC1=CC=C(N=NC=2C(=CC([NH3+])=C(C)C=2)N)C=C1N=NC1=CC(C)=C([NH3+])C=C1N WLKAMFOFXYCYDK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- OKIIEJOIXGHUKX-UHFFFAOYSA-L cadmium iodide Chemical compound [Cd+2].[I-].[I-] OKIIEJOIXGHUKX-UHFFFAOYSA-L 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 2
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000001325 yolk sac Anatomy 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- SMBSZJBWYCGCJP-UHFFFAOYSA-N 3-(diethylamino)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(N(CC)CC)=CC2=C1 SMBSZJBWYCGCJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 238000006261 Adler reaction Methods 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- GYPIAQJSRPTNTI-UHFFFAOYSA-J PoPo-3 Chemical compound [I-].[I-].[I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C1C=CN(CCC[N+](C)(C)CCC[N+](C)(C)CCCN2C=CC(=CC=CC3=[N+](C4=CC=CC=C4O3)C)C=C2)C=C1 GYPIAQJSRPTNTI-UHFFFAOYSA-J 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940075417 cadmium iodide Drugs 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- FYWSTUCDSVYLPV-UHFFFAOYSA-N nitrooxythallium Chemical compound [Tl+].[O-][N+]([O-])=O FYWSTUCDSVYLPV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229910002007 uranyl nitrate Inorganic materials 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015799P | 2014-06-23 | 2014-06-23 | |
| US62/015,799 | 2014-06-23 | ||
| US14/560,921 US9909167B2 (en) | 2014-06-23 | 2014-12-04 | On-slide staining by primer extension |
| US14/560,921 | 2014-12-04 | ||
| CN201580040230.3A CN106574301B (zh) | 2014-06-23 | 2015-06-19 | 通过引物延伸进行载玻片上染色 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580040230.3A Division CN106574301B (zh) | 2014-06-23 | 2015-06-19 | 通过引物延伸进行载玻片上染色 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113151396A true CN113151396A (zh) | 2021-07-23 |
Family
ID=54869107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110180443.3A Pending CN113151396A (zh) | 2014-06-23 | 2015-06-19 | 通过引物延伸进行载玻片上染色 |
| CN201580040230.3A Active CN106574301B (zh) | 2014-06-23 | 2015-06-19 | 通过引物延伸进行载玻片上染色 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580040230.3A Active CN106574301B (zh) | 2014-06-23 | 2015-06-19 | 通过引物延伸进行载玻片上染色 |
Country Status (7)
| Country | Link |
|---|---|
| US (11) | US9909167B2 (https=) |
| EP (2) | EP3158089B1 (https=) |
| JP (2) | JP6910145B2 (https=) |
| CN (2) | CN113151396A (https=) |
| AU (2) | AU2015280326B2 (https=) |
| CA (1) | CA2952872A1 (https=) |
| WO (1) | WO2015200139A1 (https=) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604555B1 (en) | 2011-10-14 | 2024-12-25 | President and Fellows of Harvard College | Sequencing by structure assembly |
| EP2773779B1 (en) | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| ES2991004T3 (es) | 2011-12-22 | 2024-12-02 | Harvard College | Métodos para la detección de analitos |
| US10407724B2 (en) | 2012-02-09 | 2019-09-10 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
| EP2971184B1 (en) | 2013-03-12 | 2019-04-17 | President and Fellows of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
| CA2916662C (en) | 2013-06-25 | 2022-03-08 | Prognosys Biosciences, Inc. | Methods and systems for determining spatial patterns of biological targets in a sample |
| DK3511422T3 (da) | 2013-11-12 | 2023-02-06 | Population Bio Inc | Fremgangsmåder og sammensætninger til diagnosticering, prognose og behandling af endometriose |
| US9909167B2 (en) | 2014-06-23 | 2018-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | On-slide staining by primer extension |
| WO2016007839A1 (en) | 2014-07-11 | 2016-01-14 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
| EP3901282B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| WO2017015097A1 (en) | 2015-07-17 | 2017-01-26 | Nanostring Technologies, Inc. | Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue |
| SG10202107053QA (en) | 2015-07-17 | 2021-08-30 | Nanostring Technologies Inc | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue |
| EP4354140A3 (en) | 2016-02-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Multiplexed single molecule rna visualization with a two-probe proximity ligation system |
| EP4613756A3 (en) | 2016-04-25 | 2025-11-12 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
| US11512344B2 (en) * | 2016-05-10 | 2022-11-29 | Arizona Board Of Regents On Behalf Of Arizona State University | Consecutive hybridization for multiplexed analysis of biological samples |
| EP3460474B1 (en) * | 2016-05-19 | 2022-04-06 | Toppan Printing Co., Ltd. | Method and kit for target molecule detection |
| US11352667B2 (en) | 2016-06-21 | 2022-06-07 | 10X Genomics, Inc. | Nucleic acid sequencing |
| AU2017302300B2 (en) | 2016-07-27 | 2023-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | Highly-multiplexed fluorescent imaging |
| CN118853848A (zh) | 2016-08-31 | 2024-10-29 | 哈佛学院董事及会员团体 | 将生物分子的检测组合到使用荧光原位测序的单个试验的方法 |
| DK3555313T3 (da) | 2016-12-16 | 2021-08-09 | Aratome Llc | Molekylær detektering ved hjælp af ligeringsamplifikation |
| CN120210336A (zh) | 2017-10-06 | 2025-06-27 | 10X基因组学有限公司 | Rna模板化连接 |
| US12091706B2 (en) | 2018-01-30 | 2024-09-17 | Rush University Medical Center | Sequential staining for multiplex analyses of tissues and cells |
| US20190249248A1 (en) | 2018-02-12 | 2019-08-15 | Nanostring Technologies, Inc. | Biomolecular probes and methods of detecting gene and protein expression |
| WO2019200326A1 (en) | 2018-04-13 | 2019-10-17 | Rarecyte, Inc. | Kits for labeling of biomarkers and methods of using the same |
| US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| EP4219753A3 (en) | 2018-10-19 | 2023-09-06 | Akoya Biosciences, Inc. | Detection of co-occurring receptor-coding nucleic acid segments |
| AU2019371382A1 (en) * | 2018-10-31 | 2021-05-20 | The Board Of Trustees Of The Leland Standford Junior University | Methods and kits for detecting cells using oligonucleotide conjugated antibodies |
| US12529094B2 (en) | 2018-12-10 | 2026-01-20 | 10X Genomics, Inc. | Imaging system hardware |
| WO2020123316A2 (en) | 2018-12-10 | 2020-06-18 | 10X Genomics, Inc. | Methods for determining a location of a biological analyte in a biological sample |
| EP3903104A4 (en) * | 2018-12-27 | 2022-09-21 | Bio-Rad Laboratories, Inc. | SEQUENCE MULTIPLEX WESTERN BLOT |
| US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
| US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
| US12404543B2 (en) * | 2019-04-25 | 2025-09-02 | Agilent Technologies, Inc. | Hybridization compositions and methods for making and using compositions |
| WO2020243579A1 (en) | 2019-05-30 | 2020-12-03 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| CN119220641A (zh) | 2019-05-31 | 2024-12-31 | 10X基因组学有限公司 | 检测目标核酸分子的方法 |
| CN114729391A (zh) | 2019-09-30 | 2022-07-08 | 阿科亚生物科学股份有限公司 | 用酶介导的放大的多路复用成像 |
| CN114616344B (zh) * | 2019-10-28 | 2026-03-31 | 普赛尔根技术股份公司 | 用于绘制滚环扩增产物图谱的方法 |
| WO2021092433A2 (en) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Enhancing specificity of analyte binding |
| GB201919032D0 (en) | 2019-12-20 | 2020-02-05 | Cartana Ab | Method of detecting an analyte |
| ES2982420T3 (es) | 2019-12-23 | 2024-10-16 | 10X Genomics Inc | Métodos para el análisis espacial mediante el uso de la ligazón con plantilla de ARN |
| EP4081656A1 (en) | 2019-12-23 | 2022-11-02 | 10X Genomics, Inc. | Compositions and methods for using fixed biological samples in partition-based assays |
| CN115135984B (zh) | 2019-12-23 | 2025-12-23 | 10X基因组学有限公司 | 可逆固定试剂及其使用方法 |
| US12365942B2 (en) | 2020-01-13 | 2025-07-22 | 10X Genomics, Inc. | Methods of decreasing background on a spatial array |
| US12405264B2 (en) | 2020-01-17 | 2025-09-02 | 10X Genomics, Inc. | Electrophoretic system and method for analyte capture |
| US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| US20210230681A1 (en) | 2020-01-24 | 2021-07-29 | 10X Genomics, Inc. | Methods for spatial analysis using proximity ligation |
| EP4097251A1 (en) | 2020-01-29 | 2022-12-07 | 10X Genomics, Inc. | Compositions and methods for analyte detection |
| US12076701B2 (en) | 2020-01-31 | 2024-09-03 | 10X Genomics, Inc. | Capturing oligonucleotides in spatial transcriptomics |
| US12110541B2 (en) | 2020-02-03 | 2024-10-08 | 10X Genomics, Inc. | Methods for preparing high-resolution spatial arrays |
| US12110548B2 (en) | 2020-02-03 | 2024-10-08 | 10X Genomics, Inc. | Bi-directional in situ analysis |
| US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
| US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
| WO2021158925A1 (en) | 2020-02-07 | 2021-08-12 | 10X Genomics, Inc. | Quantitative and automated permeabilization performance evaluation for spatial transcriptomics |
| US12281357B1 (en) | 2020-02-14 | 2025-04-22 | 10X Genomics, Inc. | In situ spatial barcoding |
| CN115485391A (zh) | 2020-02-17 | 2022-12-16 | 10X基因组学有限公司 | 染色质相互作用的原位分析 |
| EP4484571A3 (en) | 2020-02-21 | 2025-03-19 | 10X Genomics, Inc. | Methods and compositions for integrated in situ spatial assay |
| US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
| US12188085B2 (en) | 2020-03-05 | 2025-01-07 | 10X Genomics, Inc. | Three-dimensional spatial transcriptomics with sequencing readout |
| EP4139485B1 (en) | 2020-04-22 | 2023-09-06 | 10X Genomics, Inc. | Methods for spatial analysis using targeted rna depletion |
| EP4153776B1 (en) | 2020-05-22 | 2025-03-05 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
| EP4414459B1 (en) | 2020-05-22 | 2025-09-03 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| US12031177B1 (en) | 2020-06-04 | 2024-07-09 | 10X Genomics, Inc. | Methods of enhancing spatial resolution of transcripts |
| EP4421186B1 (en) | 2020-06-08 | 2025-08-13 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| US12209273B2 (en) | 2020-06-12 | 2025-01-28 | 10X Genomics, Inc. | Nucleic acid assays using click chemistry bioconjugation |
| ES2994976T3 (en) | 2020-06-25 | 2025-02-05 | 10X Genomics Inc | Spatial analysis of dna methylation |
| US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
| US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
| US12209280B1 (en) | 2020-07-06 | 2025-01-28 | 10X Genomics, Inc. | Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis |
| EP4182676A1 (en) | 2020-07-20 | 2023-05-24 | Akoya Biosciences, Inc. | Processing and imaging tissue samples |
| US11492662B2 (en) * | 2020-08-06 | 2022-11-08 | Singular Genomics Systems, Inc. | Methods for in situ transcriptomics and proteomics |
| US11434525B2 (en) | 2020-08-06 | 2022-09-06 | Singular Genomics Systems, Inc. | Spatial sequencing |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
| US12297499B2 (en) | 2020-08-17 | 2025-05-13 | 10X Genomics, Inc. | Multicomponent nucleic acid probes for sample analysis |
| US11981958B1 (en) | 2020-08-20 | 2024-05-14 | 10X Genomics, Inc. | Methods for spatial analysis using DNA capture |
| US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
| US12071667B2 (en) | 2020-11-04 | 2024-08-27 | 10X Genomics, Inc. | Sequence analysis using meta-stable nucleic acid molecules |
| WO2022109196A1 (en) | 2020-11-18 | 2022-05-27 | Akoya Biosciences, Inc. | Multiplexed imaging with nanobody probes |
| US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
| US12509717B2 (en) | 2020-12-11 | 2025-12-30 | 10X Genomics, Inc. | Methods and compositions for multimodal in situ analysis |
| EP4729631A2 (en) | 2020-12-21 | 2026-04-22 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
| US12060603B2 (en) | 2021-01-19 | 2024-08-13 | 10X Genomics, Inc. | Methods for internally controlled in situ assays using padlock probes |
| US12275984B2 (en) | 2021-03-02 | 2025-04-15 | 10X Genomics, Inc. | Sequential hybridization and quenching |
| EP4305196B1 (en) | 2021-04-14 | 2025-04-02 | 10X Genomics, Inc. | Methods of measuring mislocalization of an analyte |
| EP4334706A4 (en) | 2021-05-05 | 2025-08-06 | Singular Genomics Systems Inc | MULTIOMICS ANALYSIS DEVICE AND METHODS OF USE THEREOF |
| EP4320271B1 (en) | 2021-05-06 | 2025-03-19 | 10X Genomics, Inc. | Methods for increasing resolution of spatial analysis |
| CN113024665A (zh) * | 2021-05-31 | 2021-06-25 | 泛肽生物科技(浙江)有限公司 | 一种oligos标记抗体的方法及其标记得到的抗体 |
| WO2022256503A1 (en) | 2021-06-03 | 2022-12-08 | 10X Genomics, Inc. | Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis |
| AU2022317053B2 (en) | 2021-07-30 | 2025-01-02 | 10X Genomics, Inc. | Methods and compositions for synchronizing reactions in situ |
| US12139751B2 (en) | 2021-07-30 | 2024-11-12 | 10X Genomics, Inc. | Circularizable probes for in situ analysis |
| US12460251B2 (en) | 2021-08-03 | 2025-11-04 | 10X Genomics, Inc. | Stabilization and/or compaction of nucleic acid molecules |
| US12553079B2 (en) | 2021-08-03 | 2026-02-17 | 10X Genomics, Inc. | Nucleic acid concatemers and methods for stabilizing and/or compacting the same |
| US12529096B2 (en) | 2021-08-03 | 2026-01-20 | 10X Genomics, Inc. | Stabilization and/or compaction of nucleic acid structures |
| US12391984B2 (en) | 2021-08-03 | 2025-08-19 | 10X Genomics, Inc. | Compositions and methods for rolling circle amplification |
| EP4446426B1 (en) | 2021-08-16 | 2026-03-04 | 10X Genomics, Inc. | Probes comprising a split barcode region and methods of use |
| WO2023034489A1 (en) | 2021-09-01 | 2023-03-09 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
| WO2023086880A1 (en) | 2021-11-10 | 2023-05-19 | 10X Genomics, Inc. | Methods, compositions, and kits for determining the location of an analyte in a biological sample |
| WO2023102118A2 (en) | 2021-12-01 | 2023-06-08 | 10X Genomics, Inc. | Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis |
| EP4733410A2 (en) | 2022-01-21 | 2026-04-29 | 10X Genomics, Inc. | Multiple readout signals for analyzing a sample |
| CN118974836A (zh) | 2022-03-08 | 2024-11-15 | 10X基因组学有限公司 | 将光学拥挤最小化的原位代码设计方法 |
| EP4505177A1 (en) | 2022-04-01 | 2025-02-12 | 10x Genomics, Inc. | Compositions and methods for targeted masking of autofluorescence |
| WO2023215603A1 (en) | 2022-05-06 | 2023-11-09 | 10X Genomics, Inc. | Methods and compositions for in situ analysis of v(d)j sequences |
| US20240084378A1 (en) | 2022-05-11 | 2024-03-14 | 10X Genomics, Inc. | Compositions and methods for in situ sequencing |
| EP4540607A1 (en) | 2022-06-17 | 2025-04-23 | 10X Genomics, Inc. | Catalytic de-crosslinking of samples for in situ analysis |
| CN119856053A (zh) * | 2022-07-20 | 2025-04-18 | 哈佛大学校长及研究员协会 | 高度复用化、热可控的dna延伸方法及其应用 |
| WO2024040060A1 (en) | 2022-08-16 | 2024-02-22 | 10X Genomics, Inc. | Ap50 polymerases and uses thereof |
| EP4482979B1 (en) | 2022-11-09 | 2025-10-01 | 10X Genomics, Inc. | Methods, compositions, and kits for determining the location of multiple analytes in a biological sample |
| CN116287135A (zh) * | 2023-01-12 | 2023-06-23 | 华中科技大学 | Rna酶抑制剂在rna原位杂交中的用途 |
| EP4720332A1 (en) | 2023-06-01 | 2026-04-08 | Singular Genomics Systems, Inc. | Methods and probes for detecting polynucleotide sequences in cells and tissues |
| WO2025029831A1 (en) | 2023-07-31 | 2025-02-06 | 10X Genomics, Inc. | Methods and systems for targeted rna cleavage and target rna-primed rolling circle amplification |
| EP4560319A1 (en) | 2023-11-24 | 2025-05-28 | Pierre Fabre Medicament | Immune and tumour cells expression of vista in a panel of cancer indications |
| WO2025189030A1 (en) | 2024-03-07 | 2025-09-12 | Stellaromics, Inc. | Methods and systems for volumetric imaging |
| CN118496347B (zh) * | 2024-05-30 | 2024-10-25 | 北京航空航天大学杭州创新研究院 | 一种用于抗体寡核苷酸偶联的方法 |
| CN120005963B (zh) * | 2025-02-28 | 2025-11-07 | 青岛农业大学 | 一种快速计数牛奶中菌落总数的方法及染色试剂组合 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531283B1 (en) * | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
| US20070020650A1 (en) * | 2005-04-01 | 2007-01-25 | Avak Kahvejian | Methods for detecting proteins |
| WO2013113699A2 (en) * | 2012-01-30 | 2013-08-08 | Olink Ab | Hyperthermophilic polymerase enabled proximity extension assay |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000796A (en) | 1910-11-08 | 1911-08-15 | Jacob Whitfield Graham | Spring-tire. |
| US5063151A (en) * | 1985-09-20 | 1991-11-05 | Biometallics, Inc. | Immunoassay method and kit |
| US5068178A (en) * | 1988-12-06 | 1991-11-26 | Genetic Systems Corporation | Method of enhancing direct immunofluorescence staining of cells |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| AU3618593A (en) * | 1992-02-04 | 1993-09-01 | E.I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
| US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6027890A (en) | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
| US6117631A (en) * | 1996-10-29 | 2000-09-12 | Polyprobe, Inc. | Detection of antigens via oligonucleotide antibody conjugates |
| US20100081134A1 (en) | 1997-07-21 | 2010-04-01 | Mirkin Chad A | Bio-barcode based detection of target analytes |
| US5948902A (en) | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
| AU3463099A (en) | 1998-03-31 | 1999-10-18 | Tularik Inc. | High throughput assay for detection of mrna in cells |
| US8131053B2 (en) | 1999-01-25 | 2012-03-06 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
| US6316230B1 (en) | 1999-08-13 | 2001-11-13 | Applera Corporation | Polymerase extension at 3′ terminus of PNA-DNA chimera |
| US6998239B1 (en) * | 1999-10-12 | 2006-02-14 | Chemocentryx, Inc. | Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine |
| CA2413814A1 (en) | 2000-05-11 | 2002-12-12 | Synthes (U.S.A.) | Push-connection for the detachable connection of two bodies, in particular a pedicle screw and a screwdriver |
| US6511809B2 (en) * | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
| US6790636B1 (en) | 2000-06-14 | 2004-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid fluorescent labeling of tissue for microdissection using fluorescent specific binding agents |
| US6743592B1 (en) | 2000-07-25 | 2004-06-01 | The Trustees Of The University Of Pennsylvania | Methods, systems and kits for immuno-detection of epitopes expressed on molecules |
| US20040038194A1 (en) | 2000-10-06 | 2004-02-26 | Hofmann Scott Daniel | Diagnostic polymerase chain reaction process utilizing simultaneous capture and detection of amplicons |
| US20020072053A1 (en) * | 2000-12-08 | 2002-06-13 | Mcnally Alan J. | Immunoassay based on DNA replication using labeled primer |
| US7846746B2 (en) | 2001-04-10 | 2010-12-07 | Children's Medical Center Corporation | Methods of analysis and labeling of protein-protein interactions |
| EP1270738A1 (de) | 2001-06-18 | 2003-01-02 | chimera biotec GmbH | Verfahren zum Nachweis von Substanzen in Flüssigkeiten |
| AU2002305478A1 (en) | 2001-06-20 | 2003-01-08 | Molecular Staging, Inc. | Conjugates of reduced antibodies and biomolecules |
| US7341831B2 (en) | 2001-07-18 | 2008-03-11 | The Trustees Of The University Of Pennsylvania | Method for immuno-detection of epitopes |
| US20040091857A1 (en) * | 2001-07-20 | 2004-05-13 | Nallur Girish N. | Gene expression profiling |
| US6658780B2 (en) | 2001-09-06 | 2003-12-09 | Aris Papadimas | Revolver device |
| JP3926178B2 (ja) * | 2001-11-02 | 2007-06-06 | 富士通株式会社 | 蛋白質検出デバイス |
| AU2003209340A1 (en) * | 2002-01-18 | 2003-09-02 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
| AU2003222178A1 (en) | 2002-03-29 | 2003-10-13 | Nugen Technologies, Inc. | Single primer isothermal nucleic acid amplification-enhanced analyte detection and quantification |
| ATE432365T1 (de) * | 2003-02-21 | 2009-06-15 | Geneform Technologies Ltd | Verfahren, kits und reagenzien zur nukleinsäuresequenzierung |
| US20040185453A1 (en) * | 2003-03-21 | 2004-09-23 | Joel Myerson | Affinity based methods for separating homologous parental genetic material and uses thereof |
| CN101410530B (zh) * | 2003-04-18 | 2013-03-27 | 贝克顿·迪金森公司 | 免疫-扩增 |
| US7198900B2 (en) | 2003-08-29 | 2007-04-03 | Applera Corporation | Multiplex detection compositions, methods, and kits |
| US7341837B2 (en) * | 2003-09-02 | 2008-03-11 | Lawton Robert L | Soluble analyte detection and amplification |
| WO2005054514A1 (en) * | 2003-12-02 | 2005-06-16 | Agency For Science, Technology And Research | Immuno-amplification rna assay |
| KR100695123B1 (ko) | 2003-12-03 | 2007-03-14 | 삼성전자주식회사 | Ｔｍ에 따라 기판상에 고정화된 프로브 폴리뉴클레오티드군을 2이상 포함하는 폴리뉴클레오티드 어레이 및 그를이용하는 표적 핵산 검출 방법 |
| US20050233340A1 (en) | 2004-04-20 | 2005-10-20 | Barrett Michael T | Methods and compositions for assessing CpG methylation |
| DK1842226T3 (da) | 2004-11-03 | 2010-10-18 | Iris Molecular Diagnostics Inc | Homogen analytpåvisning |
| CA2598508A1 (fr) | 2005-02-25 | 2006-08-31 | Commissariat A L'energie Atomique | Procede et dispositif pour separer des cibles moleculaires dans un melange complexe |
| WO2006128010A2 (en) | 2005-05-26 | 2006-11-30 | The Trustees Of Boston University | Quantification of nucleic acids and proteins using oligonucleotide mass tags |
| US20070026430A1 (en) | 2005-06-30 | 2007-02-01 | Applera Corporation | Proximity probing of target proteins comprising restriction and/or extension |
| WO2007117700A2 (en) | 2006-04-07 | 2007-10-18 | The Trustees Of The University Of Pennsylvania | In situ cloning from pathological tissue specimens |
| CA2656525A1 (en) * | 2006-06-30 | 2008-01-10 | Applera Corporation | Reversible terminator nucleotides and methods of use |
| US20080124735A1 (en) * | 2006-10-16 | 2008-05-29 | Matthias Schuster | Method for detection of one or more CpG positions |
| WO2008052774A2 (en) | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
| US9201063B2 (en) | 2006-11-16 | 2015-12-01 | General Electric Company | Sequential analysis of biological samples |
| US8305579B2 (en) | 2006-11-16 | 2012-11-06 | Thomas Pirrie Treynor | Sequential analysis of biological samples |
| SE531135C2 (sv) | 2006-12-01 | 2008-12-23 | Alf Maansson | Känslig detektion av gifter, patogener och sjukdomsmarkörer genom aggregation av cytoskeletala filament |
| WO2008076375A2 (en) | 2006-12-13 | 2008-06-26 | Autogenomics, Inc. | Concurrent analysis of multiple patient samples using solid phase addressable multiplex test with high signal-to-noise ratio |
| CN101210270A (zh) | 2006-12-31 | 2008-07-02 | 陕西北美基因股份有限公司 | 病毒病原高通量快速排查检测方法 |
| GB0703996D0 (en) * | 2007-03-01 | 2007-04-11 | Oxitec Ltd | Nucleic acid detection |
| US8003314B2 (en) | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
| WO2009012220A2 (en) * | 2007-07-17 | 2009-01-22 | Agilent Technologies Inc. | Analyte detection assays |
| WO2009064933A2 (en) | 2007-11-13 | 2009-05-22 | Ikonisys, Inc. | Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope |
| WO2009126678A2 (en) | 2008-04-08 | 2009-10-15 | Cornell University | Detection of target nucleic acid sequences using fluorescence resonance energy transfer |
| US20100021904A1 (en) | 2008-05-21 | 2010-01-28 | Pierce Niles A | Shielded cross-linking probes |
| US8530156B2 (en) | 2008-08-08 | 2013-09-10 | President And Fellows Of Harvard College | Chemically cleavable phosphoramidite linkers for sequencing by ligation |
| US8685937B2 (en) | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
| US8262879B2 (en) | 2008-09-03 | 2012-09-11 | Nabsys, Inc. | Devices and methods for determining the length of biopolymers and distances between probes bound thereto |
| US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
| US8309306B2 (en) | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
| US8993245B2 (en) | 2008-11-21 | 2015-03-31 | Mediomics, Llc | Biosensor for detecting multiple epitopes on a target |
| DE102008062372B3 (de) | 2008-12-17 | 2010-06-17 | Medizinische Hochschule Hannover | Nachweiskonjugat und Verfahren zur Analyse |
| WO2010115089A2 (en) | 2009-04-03 | 2010-10-07 | University Of Virginia Patent Foundation | Serial multiple antigen colocalization in paraffin-embedded tissue |
| US9284559B2 (en) | 2009-04-14 | 2016-03-15 | Wake Forest University Health Sciences | Multivalent aptamer complexes |
| CN102459298A (zh) | 2009-05-05 | 2012-05-16 | 阿尔特姆恩科技责任有限公司 | 化学可编程免疫 |
| US9677125B2 (en) * | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
| US20130059741A1 (en) * | 2010-05-13 | 2013-03-07 | Illumina, Inc. | Binding assays for markers |
| US8658780B2 (en) | 2010-05-18 | 2014-02-25 | California Institute Of Technology | Triggered covalent probes for imaging and silencing genetic expression |
| US20120004132A1 (en) | 2010-07-02 | 2012-01-05 | Affymetrix, Inc. | Detection of Nucleic Acids and Proteins |
| WO2012018397A2 (en) | 2010-08-02 | 2012-02-09 | The Regents Of The University Of California | Molecular subtyping of oral squamous cell carcinoma to distinguish a subtype that is unlikely to metastasize |
| US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
| WO2012057689A1 (en) * | 2010-10-29 | 2012-05-03 | Ge Healthcare Bio-Sciences Ab | Proximity ligation technology for western blot applications |
| WO2012058638A2 (en) | 2010-10-29 | 2012-05-03 | President And Fellows Of Harvard College | Nucleic acid nanostructure barcode probes |
| EP3574990B1 (en) | 2010-11-01 | 2022-04-06 | Bio-Rad Laboratories, Inc. | System for forming emulsions |
| US20120258870A1 (en) | 2010-11-22 | 2012-10-11 | The University Of Chicago | Methods, Systems, and/or Use of Oligonucleotide Conjugates to Develop Panels for Use in Assays and Detections |
| US20120178081A1 (en) | 2010-12-31 | 2012-07-12 | Affymetrix. Inc. | Methods of Labeling Cells, Labeled Cells, and uses Thereof |
| EP3567121B1 (en) * | 2011-01-17 | 2023-08-30 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
| GB201101621D0 (en) * | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| US20120252682A1 (en) * | 2011-04-01 | 2012-10-04 | Maples Corporate Services Limited | Methods and systems for sequencing nucleic acids |
| US20140170653A1 (en) * | 2011-04-15 | 2014-06-19 | Life Technologies Corporation | Chemical ligation |
| US8946389B2 (en) | 2011-04-25 | 2015-02-03 | University Of Washington | Compositions and methods for multiplex biomarker profiling |
| GB201107863D0 (en) | 2011-05-11 | 2011-06-22 | Olink Ab | Method and product |
| GB201108678D0 (en) * | 2011-05-24 | 2011-07-06 | Olink Ab | Multiplexed proximity ligation assay |
| US9938524B2 (en) * | 2011-11-22 | 2018-04-10 | Active Motif, Inc. | Multiplex isolation of protein-associated nucleic acids |
| US10689643B2 (en) * | 2011-11-22 | 2020-06-23 | Active Motif, Inc. | Targeted transposition for use in epigenetic studies |
| EP4249605B1 (en) * | 2011-12-22 | 2024-08-28 | President And Fellows Of Harvard College | Methods for analyte detection |
| US9267168B2 (en) | 2012-06-12 | 2016-02-23 | Pacific Biosciences Of California, Inc. | Methods and compositions for isolating template nucleic acids |
| WO2013188756A1 (en) | 2012-06-15 | 2013-12-19 | The University Of Chicago | Oligonucleotide-mediated quantitative multiplexed immunoassays |
| US9707562B2 (en) | 2013-03-13 | 2017-07-18 | Denovo Sciences, Inc. | System for capturing and analyzing cells |
| EP2971141B1 (en) | 2013-03-15 | 2018-11-28 | Genapsys, Inc. | Systems for biological analysis |
| WO2014182283A1 (en) | 2013-05-07 | 2014-11-13 | Empire Technology Development Llc | Terahertz frequency tags and methods for their preparation and use |
| ES2754177T3 (es) | 2013-06-12 | 2020-04-16 | Massachusetts Gen Hospital | Métodos para la detección multiplexada de moléculas diana y sus usos |
| CN105555972B (zh) * | 2013-07-25 | 2020-07-31 | 伯乐生命医学产品有限公司 | 遗传测定 |
| CA2919833A1 (en) | 2013-07-30 | 2015-02-05 | President And Fellows Of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
| US9193359B2 (en) | 2013-08-12 | 2015-11-24 | GM Global Technology Operations LLC | Vehicle systems and methods for identifying a driver |
| EP3049067A4 (en) * | 2013-09-24 | 2017-05-03 | The Regents of the University of California | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them |
| DK3063291T3 (da) | 2013-10-11 | 2019-05-06 | Ventana Med Syst Inc | Multiplex her2 og østrogenreceptor co-farvnings-assays til påvisning af tumorheterogenitet |
| US9834814B2 (en) | 2013-11-22 | 2017-12-05 | Agilent Technologies, Inc. | Spatial molecular barcoding of in situ nucleic acids |
| GB201401885D0 (en) | 2014-02-04 | 2014-03-19 | Olink Ab | Proximity assay with detection based on hybridisation chain reaction (HCR) |
| US10294510B2 (en) | 2014-03-11 | 2019-05-21 | President And Fellows Of Harvard College | High-throughput and highly multiplexed imaging with programmable nucleic acid probes |
| US9753036B2 (en) * | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| WO2015191666A2 (en) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Raf1 fusions |
| WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
| US9909167B2 (en) | 2014-06-23 | 2018-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | On-slide staining by primer extension |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| US9625387B2 (en) | 2014-09-16 | 2017-04-18 | Lawrence Livermore National Security, Llc | System and method for controlling depth of imaging in tissues using fluorescence microscopy under ultraviolet excitation following staining with fluorescing agents |
| US10071121B2 (en) | 2014-11-14 | 2018-09-11 | San Diego State University (Sdsu) Foundation | Cardiac, mesenchymal and endothelial progenitor cell (CPC) chimeras and methods for making and using them |
| US10731202B2 (en) | 2014-11-24 | 2020-08-04 | Battelle Memorial Institute | Chromatin activity precipitation method and system |
| US10006917B2 (en) | 2014-12-15 | 2018-06-26 | President And Fellows Of Harvard College | Methods and compositions relating to super-resolution imaging and modification |
| US20180095067A1 (en) | 2015-04-03 | 2018-04-05 | Abbott Laboratories | Devices and methods for sample analysis |
| WO2016168825A1 (en) | 2015-04-17 | 2016-10-20 | Centrillion Technology Holdings Corporation | Methods for performing spatial profiling of biological molecules |
| SG10202107053QA (en) | 2015-07-17 | 2021-08-30 | Nanostring Technologies Inc | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue |
| KR102557419B1 (ko) | 2015-08-07 | 2023-07-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 단백질-단백질 상호작용의 초해상도 영상화 |
| EP4101932A1 (en) | 2016-05-15 | 2022-12-14 | Ultivue, Inc. | Multiplexed imaging using strand displacement |
| US20170349949A1 (en) | 2016-06-03 | 2017-12-07 | Partikula Llc | Methods of selecting subjects for treatment with metabolic modulators |
| AU2017302300B2 (en) | 2016-07-27 | 2023-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | Highly-multiplexed fluorescent imaging |
| US11099170B2 (en) | 2018-06-13 | 2021-08-24 | The Board Of Trustees Of The University Of Illinois | Parallel DNA detection by solid-state multi-pore systems and associated methods |
-
2014
- 2014-12-04 US US14/560,921 patent/US9909167B2/en active Active
-
2015
- 2015-06-19 EP EP15811607.9A patent/EP3158089B1/en active Active
- 2015-06-19 CN CN202110180443.3A patent/CN113151396A/zh active Pending
- 2015-06-19 US US15/317,019 patent/US20170107563A1/en not_active Abandoned
- 2015-06-19 AU AU2015280326A patent/AU2015280326B2/en active Active
- 2015-06-19 WO PCT/US2015/036763 patent/WO2015200139A1/en not_active Ceased
- 2015-06-19 EP EP20199757.4A patent/EP3822362B1/en active Active
- 2015-06-19 JP JP2016574911A patent/JP6910145B2/ja active Active
- 2015-06-19 CA CA2952872A patent/CA2952872A1/en active Pending
- 2015-06-19 CN CN201580040230.3A patent/CN106574301B/zh active Active
-
2017
- 2017-12-05 US US15/832,627 patent/US10006082B2/en active Active
- 2017-12-05 US US15/832,595 patent/US10017808B2/en active Active
- 2017-12-05 US US15/832,621 patent/US10000796B2/en active Active
-
2019
- 2019-01-04 US US16/240,463 patent/US11299770B2/en active Active
- 2019-11-11 US US16/679,769 patent/US10982263B2/en active Active
-
2021
- 2021-02-25 US US17/185,757 patent/US11634753B2/en active Active
- 2021-07-05 JP JP2021111337A patent/JP2021164471A/ja active Pending
-
2022
- 2022-02-15 US US17/672,552 patent/US11926865B2/en active Active
- 2022-03-03 AU AU2022201480A patent/AU2022201480A1/en not_active Abandoned
-
2023
- 2023-03-02 US US18/177,750 patent/US12331344B2/en active Active
-
2025
- 2025-04-28 US US19/192,218 patent/US20250313883A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531283B1 (en) * | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
| US20070020650A1 (en) * | 2005-04-01 | 2007-01-25 | Avak Kahvejian | Methods for detecting proteins |
| WO2013113699A2 (en) * | 2012-01-30 | 2013-08-08 | Olink Ab | Hyperthermophilic polymerase enabled proximity extension assay |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331344B2 (en) | On-slide staining by primer extension | |
| EP3490616B1 (en) | Highly-multiplexed fluorescent imaging | |
| HK40057000A (en) | On-slide staining by primer extension | |
| HK40009147B (en) | Highly-multiplexed fluorescent imaging | |
| HK40009147A (en) | Highly-multiplexed fluorescent imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40057000 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210723 |
|
| WD01 | Invention patent application deemed withdrawn after publication |